Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced in...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-06-01
|
| Series: | Revista Brasileira de Hematologia e Hemoterapia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099&lng=en&tlng=en |
| _version_ | 1818294679072931840 |
|---|---|
| author | Ana Marcela Rojas Fonseca-Hial Katya Parisio Jose Salvador Rodrigues Oliveira |
| author_facet | Ana Marcela Rojas Fonseca-Hial Katya Parisio Jose Salvador Rodrigues Oliveira |
| author_sort | Ana Marcela Rojas Fonseca-Hial |
| collection | DOAJ |
| description | ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy. |
| first_indexed | 2024-12-13T03:35:35Z |
| format | Article |
| id | doaj.art-70349a45e102450abc395b705bc942a3 |
| institution | Directory Open Access Journal |
| issn | 1806-0870 |
| language | English |
| last_indexed | 2024-12-13T03:35:35Z |
| publishDate | 2016-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Revista Brasileira de Hematologia e Hemoterapia |
| spelling | doaj.art-70349a45e102450abc395b705bc942a32022-12-22T00:01:03ZengElsevierRevista Brasileira de Hematologia e Hemoterapia1806-08702016-06-013829910510.1016/j.bjhh.2016.02.006S1516-84842016000200099Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disordersAna Marcela Rojas Fonseca-HialKatya ParisioJose Salvador Rodrigues OliveiraABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099&lng=en&tlng=enHematopoietic stem cell transplantIndolent lymphoproliferative disorderReduced intensity conditioningGraft-versus-lymphomaAllogeneic |
| spellingShingle | Ana Marcela Rojas Fonseca-Hial Katya Parisio Jose Salvador Rodrigues Oliveira Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders Revista Brasileira de Hematologia e Hemoterapia Hematopoietic stem cell transplant Indolent lymphoproliferative disorder Reduced intensity conditioning Graft-versus-lymphoma Allogeneic |
| title | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
| title_full | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
| title_fullStr | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
| title_full_unstemmed | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
| title_short | Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
| title_sort | allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
| topic | Hematopoietic stem cell transplant Indolent lymphoproliferative disorder Reduced intensity conditioning Graft-versus-lymphoma Allogeneic |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099&lng=en&tlng=en |
| work_keys_str_mv | AT anamarcelarojasfonsecahial allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders AT katyaparisio allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders AT josesalvadorrodriguesoliveira allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders |